Crossmark

Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours

Crossref DOI link: https://doi.org/10.1186/s40658-019-0243-1

Published Online: 2019-04-25

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Levart, D. https://orcid.org/0000-0001-5893-0700
Kalogianni, E.

Corcoran, B.

Mulholland, N.

Vivian, G.
License Information

Text and Data Mining valid from 2019-04-25
More Information

Article History

Received: 1 August 2018

Accepted: 8 February 2019

First Online: 25 April 2019

Ethics approval and consent to participate

: This retrospective study comprised anonymised data acquired as part of the standard departmental therapy protocol. Our institutional Research and Development team confirmed that Research Ethics Committee approval was not required for this type of study.

: Not applicable.

: DL has received financial support for attending a symposium from Imaging Equipment Ltd. GV has received a speaker honorarium from Advanced Accelerator Applications and has had an advisory board position for Imaging Equipment Ltd. All other authors declare they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.